跳到正文
← 返回论文列表与筛选
阅读说明

本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。

DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。

引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。

关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。

分类依据与纠错

AI 根据所提供的论文材料归类:摘要聚焦癌症分子条件依赖图,未明确涉及经济社会网络、干扰或所列其他方向。

反馈分类问题

Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer

无向图模型中的贝叶斯边回归:刻画癌症患者间异质性

正在核对关联版本…

代码、数据与补充材料

正在核对对应版本的资源…

关注这篇论文的作者
Zeya Wang
Ahmed O. Kaseb
Hesham M. Amin
Manal M. Hassan
Wenyi Wang
Jeffrey S. Morris

无向图模型中的贝叶斯边回归:刻画癌症患者间异质性

研究问题
当患者层面的预后指标和肿瘤纯度影响蛋白质网络时,如何估计随个体协变量变化的条件依赖,而非单一总体图?
方法与思路
作者提出无向图的边回归模型,将条件依赖建模为个体协变量的函数,通过调整肿瘤纯度的模拟与肝癌蛋白数据评估。
材料陈述的贡献
摘要称应用中网络连通性随 HepatoScore 增加,并识别不同评分下的枢纽基因及重要连接,提供潜在生物学线索。
阅读关注点
应核对协变量如何进入边参数、图结构约束和贝叶斯不确定性表达,以及疾病严重程度与连通性的关系是否稳健。
阅读边界
仅据 OpenAlex 索引摘要,稿件版本未注明;条件依赖不能直接说明生物因果机制或治疗效果,先验细节未提供,不能推断刊本变化。

原文摘要

It is well-established that interpatient heterogeneity in cancer may significantly affect genomic data analyses and in particular, network topologies. Most existing graphical model methods estimate a single population-level graph for genomic or proteomic network. In many investigations, these networks depend on patient-specific indicators that characterize the heterogeneity of individual networks across subjects with respect to subject-level covariates. Examples include assessments of how the network varies with patient-specific prognostic scores or comparisons of tumor and normal graphs while accounting for tumor purity as a continuous predictor. In this paper, we propose a novel edge regression model for undirected graphs, which estimates conditional dependencies as a function of subject-level covariates. We evaluate our model performance through simulation studies focused on comparing tumor and normal graphs while adjusting for tumor purity. In application to a dataset of proteomic measurements on plasma samples from patients with hepatocellular carcinoma (HCC), we ascertain how blood protein networks vary with disease severity, as measured by HepatoScore, a novel biomarker signature measuring disease severity. Our case study shows that the network connectivity increases with HepatoScore and a set of hub genes as well as important gene connections are identified under different HepatoScore, which may provide important biological insights to the development of precision therapies for HCC.

笔记与分组